Interrelationship between Reduction in Weight and Adiposity Indices and Improvement in Cardiovascular (CV) Death and Heart Failure (HF) Outcomes with Empagliflozin in Patients with Type 2 Diabetes (T2D) in EMPA-REG OUTCOME®